Video

Dr. Tempero Discusses Hereditary Pancreatic Cancer

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Some types of hereditary pancreatic cancer can be defined by a genetic alteration, such as the BRCA mutation syndromes or hereditary nonpolyposis colorectal cancer syndromes. However, there are also patients that do not have a known genetic determinant but yet pancreatic cancer still seems to run in the family.

If an individual has one affected first-degree relative, their risk goes up, Tempero says. The risk continues to increase as the number of first-degree relatives diagnosed with pancreatic cancer increases. Tempero says there are a number of these families that are being followed. It is likely, Tempero says, that each family has a different genetic reason for getting this cancer. Therefore, there is not a common genetic mutation and each family needs to be investigated separately.

<<<

View more from the 2014 World GI Congress

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Jordyn Silverstein, MD
Rachel N. Grisham, MD
Toon Van Gorp, MD, PhD
Paul G. Richardson, MD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer